WithdrawnNot Applicable

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Stopped: Abandoned prior to launch.

0Started 2024-11

Plain-language summary

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Sample collection or biopsy of tumor is clinically indicated as part of SOC * Prior to preceding onto therapy for treatment Exclusion Criteria: * Unable to obtain sufficient sample

What they're measuring

Best overall response (BOR)

Timeframe: up to 24 months

Trial details

NCT IDNCT04985357

SponsorTravera Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-05

View on ClinicalTrials.gov More Stage III Breast Cancer trials